home / stock / pypd / pypd news

PYPD News and Press, PolyPid Ltd. From 03/11/25

Stock Information
Company Name: PolyPid Ltd.
Stock Symbol: PYPD
Market: NASDAQ
Website: polypid.com
Menu
PYPD PYPD Quote PYPD Short PYPD News PYPD Articles PYPD Message Board
Get PYPD Alerts

News, Short Squeeze, Breakout and More Instantly...
PYPD - PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX??? for the Prevention of Abdominal Colorectal Surgical Site Infections

PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phas...
PYPD - PolyPid to Participate in the 37th Annual ROTH Conference

PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37...

PYPD - PolyPid targets SHIELD II trial completion with top-line results in Q2 2025

2025-02-12 10:44:34 ET More on PolyPid PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on PolyPid Historical earnings data for PolyPid Financial information for PolyPid Read the full article on Seeking Alpha ...

PYPD - PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

2025-02-12 10:44:06 ET PolyPid Ltd. (PYPD) Q4 2024 Results Conference Call February 12, 2025 08:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financia...
PYPD - PolyPid GAAP EPS of -$1.13 misses by $0.31

2025-02-12 07:11:43 ET More on PolyPid Seeking Alpha’s Quant Rating on PolyPid Historical earnings data for PolyPid Financial information for PolyPid Read the full article on Seeking Alpha For further details see: PolyPid GAAP EPS of -$1.13...

PYPD - PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in March 202 ...

PYPD - Expected US Company Earnings on Wednesday, February 12th, 2025

Citius Pharmaceuticals Inc. (CTXR) is expected to report $-1.25 for Q1 2025 Casio Computer Co Ltd ADR (CSIOY) is expected to report for Q3 2025 Dundee Precious Metals Inc. (DPMLF) is expected to report $0.45 for Q4 2024 Elite Pharmaceuticals, Inc. (ELTP) is expected to report for Q3 2...
PYPD - PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Opp...

PYPD - PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 fin...

PYPD - PolyPid files for secondary offering

2025-01-21 16:30:04 ET More on PolyPid PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on PolyPid Historical earnings data for PolyPid Financial information for PolyPid Read the full article on Seeking Alpha ...
Previous 10 Next 10